Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 248 of the 249 references it cites were found in a registry or an index.
Abstract
In vivo exploration of activated microglia in neurodegenerative diseases is achievable by Positron Emission Tomography (PET) imaging, using dedicated radiopharmaceuticals targeting the translocator protein-18 kDa (TSPO). In this review, we emphasized the major advances made over the last 20 years, thanks to TSPO PET imaging, to define the pathophysiological implication of microglia activation and neuroinflammation in neurodegenerative diseases, including Parkinson’s disease, Huntington’s disease, dementia, amyotrophic lateral sclerosis, multiple sclerosis, and also in psychiatric disorders. The extent and upregulation of TSPO as a molecular biomarker of activated microglia in the human brain is now widely documented in these pathologies, but its significance, and especially its protective or deleterious action regarding the disease’s stage, remains under debate. Thus, we exposed new and plausible suggestions to enhance the contribution of TSPO PET imaging for biomedical research by exploring microglia’s role and interactions with other cells in brain parenchyma. Multiplex approaches, associating TSPO PET radiopharmaceuticals with other biomarkers (PET imaging of cellular metabolism, neurotransmission or abnormal protein aggregates, but also other imaging modalities, and peripheral cytokine levels measurement and/or metabolomics analysis) was considered. Finally, the actual clinical impact of TSPO PET imaging as a routine biomarker of neuroinflammation was put into perspective regarding the current development of diagnostic and therapeutic strategies for neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The translocator protein, a hallmark of activated microglia, serves as the gold standard for PET-based neuroinflammation imaging [57].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [57]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Methods to image microglia exist and are being used to test the effect of treatments on microglia205–210.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [206]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Diagnostic and Statistical Manual of Mental Disorders(DSM)
(2008) · Encyclopedia of Counseling · doi:10.4135/9781412963978.n182 · Cited by 10,830
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“MCI represents a diagnostic entity for the transition between normal aging and AD dementia [113].”
BackgroundPolazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366 · cited 1×
“HD is neuropathologically characterized by the formation of intranuclear inclusions of mHTT [81] resulting in striatal, cortical and hypothalamic atrophy [82,83] which are associated with an accumulation of reactive microglia in these same regions [31,84].”
BackgroundResting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827 · cited 1×
“Several cellular actors including neurons, astrocytes, T-cells and the blood brain barrier (BBB) modulate microglial function and form a very dynamic network [5].”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 1×
“, amoeboid, rod, multi-nucleated, epithelioid or dystrophic state) and functional changes of microglia, known as microglial “activation” [6,9].”
Background
Cited by
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046
Global brain inflammation in stroke
Shi, K., Tian, D.-C., Li, Z.-G., Ducruet, A. F., Lawton, M. T., & Shi, F.-D. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30078-x · Cited by 911
La Joie, R., Visani, A. V., Baker, S. L., Brown, J. A., Bourakova, V., Cha, J., Chaudhary, K., Edwards, L., Iaccarino, L., Janabi, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5732 · Cited by 612
Microglia Mediated Neuroinflammation in Parkinson’s Disease
Isik, S., Yeman Kiyak, B., Akbayir, R., Seyhali, R., & Arpaci, T. (2023) · Cells · doi:10.3390/cells12071012 · Cited by 379
Microglia in multiple sclerosis: Friend or foe
Guerrero, B. L., & Sicotte, N. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00374 · Cited by 215
“Translocator Protein (TSPO) is located in the outer mitochondrial membrane and is upregulated in activated microglia (46, 47).”
BackgroundInfluentialNarayanaswami, V., Dahl, K., Bernard-Gauthier, V., Josephson, L., Cumming, P., & Vasdev, N. (2018) · Molecular Imaging · doi:10.1177/1536012118792317 · Cited by 213
“Furthermore, available TSPO ligands do not distinguish between pro- and anti-inflammatory microglia, which might be differentially expressed at the onset and progression of a neuroinflammatory condition.(74) In any event, TSPO is just one aspect of inflammatory responses, and there is a need to develop PET tracers tar…”
BackgroundMicroglial activation and tau burden predict cognitive decline in Alzheimer’s disease
Malpetti, M., Kievit, R. A., Passamonti, L., Jones, P. S., Tsvetanov, K. A., Rittman, T., Mak, E., Nicastro, N., Bevan-Jones, W. R., Su, L., et al. (2020) · Brain · doi:10.1093/brain/awaa088 · Cited by 194
Recent developments on PET radiotracers for TSPO and their applications in neuroimaging
Zhang, L., Hu, K., Shao, T., Hou, L., Zhang, S., Ye, W., Josephson, L., Meyer, J. H., Zhang, M.-R., Vasdev, N., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.006 · Cited by 184
TSPO in diverse CNS pathologies and psychiatric disease: a critical review and a way forward
Guilarte, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.003 · Cited by 173
“ligand RPK11195, has facilitated this work [Dolle et al., 2009; Cumming et al., 2017; Dupont et al., 2017].”
BackgroundBiomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Zhang, S.-S., Zhu, L., Peng, Y., Zhang, L., Chao, F.-L., Jiang, L., Xiao, Q., Liang, X., Tang, J., Yang, H., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02401-5 · Cited by 138
“In addition, it was reported that translocation protein 18 kDa (TSPO) signaling, a radioactive indicator of microglial activity [34], was reduced in TREM2−/− mice and TREM2 T66M mutant mice, and FDG uptake was decreased in TREM2−/− mice and homozygous TREM2 p-T66M knock-in mice [35, 36], suggesting that TREM2-dependen…”
BackgroundLi, H., Sagar, A. P., & Kéri, S. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.011 · Cited by 146
“However, [(18)F]FEPPA displays a high, selective, and specific binding affinity for TSPO, which is increased during induced neuroinflammation (Dupont et al., 2017; Rusjan et al., 2011; Wilson et al., 2008).”
The Translocator Protein (TSPO) in Mitochondrial Bioenergetics and Immune Processes
Betlazar, C., Middleton, R. J., Banati, R., & Liu, G.-J. (2020) · Cells · doi:10.3390/cells9020512 · Cited by 129
Lavisse, S., Goutal, S., Wimberley, C., Tonietto, M., Bottlaender, M., Gervais, P., Kuhnast, B., Peyronneau, M.-A., Barret, O., Lagarde, J., et al. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.11.011 · Cited by 127
Mueller, C., Lin, J. C., Sheriff, S., Maudsley, A. A., & Younger, J. (2019) · Brain Imaging and Behavior · doi:10.1007/s11682-018-0029-4 · Cited by 133
“Because TSPO binding is increased when microglia are in a proinflammatory state, increased PET binding is used as a marker of neuroinflammation (Alam et al. 2017; Dupont et al. 2017).”
BackgroundFilling the gaps on stroke research: Focus on inflammation and immunity
Levard, D., Buendía, I., Lanquetin, A., Glavan, M., Vivien, D., & Rubio, M. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.09.025 · Cited by 131
“However, it is worth to mention that translocator protein is also expressed by monocytes or macrophages and to a lesser extent, by astrocytes, reducing the specificity of the technique (Dupont et al., 2017).”
Li, H., Sagar, A. P., & Kéri, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.021 · Cited by 102
Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies
Mallick, R., Basak, S., Chowdhury, P., Bhowmik, P., Das, R. K., Banerjee, A., Paul, S., Pathak, S., & Duttaroy, A. K. (2025) · Pharmaceuticals · doi:10.3390/ph18010104 · Cited by 119
“PET tracers targeting translocator protein 18 kDa (TSPO), a marker of activated microglia, allow for spatial and temporal resolution of inflammatory processes in the brain [159–162].”
Staffaroni, A., Elahi, F., McDermott, D., Marton, K., Karageorgiou, E., Sacco, S., Paoletti, M., Caverzasi, E., Hess, C., Rosen, H., et al. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1608808 · Cited by 91
Best, L. A., Ghadery, C., Pavese, N., Tai, Y., & Strafella, A. P. (2019) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-019-0934-y · Cited by 95
Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy
Malpetti, M., Passamonti, L., Rittman, T., Jones, P. S., Vázquez Rodríguez, P., Bevan‐Jones, W. R., Hong, Y. T., Fryer, T. D., Aigbirhio, F. I., O'Brien, J. T., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25911 · Cited by 83
In vivo Imaging of Glial Activation in Alzheimer's Disease
Edison, P., Donat, C. K., & Sastre, M. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00625 · Cited by 86
Challenges and Opportunities in Central Nervous System Drug Discovery
Danon, J. J., Reekie, T. A., & Kassiou, M. (2019) · Trends in Chemistry · doi:10.1016/j.trechm.2019.04.009 · Cited by 89
PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area
Verger, A., Kas, A., Darcourt, J., & Guedj, É. (2022) · Cancers · doi:10.3390/cancers14051103 · Cited by 78
“Its expression in the brain increases in neurodegenerative inflammatory diseases and cancer and is related to the activation of brain auto-immune cells [107].”
BackgroundGong, J., Szego, É. M., Leonov, A., Benito, E., Becker, S., Fischer, A., Zweckstetter, M., Outeiro, T., & Schneider, A. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.2070-18.2019 · Cited by 66
Taddei, C., & Pike, V. W. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0073-4 · Cited by 60
Attwells, S., Setiawan, E., Rusjan, P., Xu, C., Hutton, C., Rafiei, D., Varughese, B., Kahn, A., Kish, S. J., Vasdev, N., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.03.007 · Cited by 64
Biswas, L., Zhou, X., Dhillon, B., Graham, A., & Shu, X. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx319 · Cited by 60
Quantitative positron emission tomography in brain research
Heurling, K., Leuzy, A., Jonasson, M., Frick, A., Zimmer, E. R., Nordberg, A. K., & Lubberink, M. (2017) · Brain Research · doi:10.1016/j.brainres.2017.06.022 · Cited by 64
The role of allopregnanolone in depressive-like behaviors: Focus on neurotrophic proteins
Almeida, F. B., Nin, M. S., & Barros, H. M. T. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2020.100218 · Cited by 53
“(Dupont et al., 2017; McNeela et al., 2018), the specificity of this target must be further investigated and its role in other disorders must be considered as well.”
BackgroundAn update into the medicinal chemistry of translocator protein (TSPO) ligands
Barresi, E., Robello, M., Costa, B., Pozzo, E. D., Baglini, E., Salerno, S., Settimo, F. D., Martini, C., & Taliani, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112924 · Cited by 62
Imaging Inflammation with Positron Emission Tomography
Iking, J., Staniszewska, M., Kessler, L., Klose, J. M., Lückerath, K., Fendler, W. P., Herrmann, K., & Rischpler, C. (2021) · Biomedicines · doi:10.3390/biomedicines9020212 · Cited by 64
“Another well‐characterized inflammation imaging target, especially in the field of neuroimaging, is the 18‐kDa mitochondrial translocator protein (TSPO), which is up‐ regulated in activated microglia and systemic monocytes [131].”
BackgroundCui, Y., Pan, M., Ma, J., Song, X., Cao, W., & Zhang, P. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03926-0 · Cited by 52
TSPO PET Imaging: From Microglial Activation to Peripheral Sterile Inflammatory Diseases?
Largeau, B., Dupont, A.-C., Guilloteau, D., Ribeiro, M. J., & Arlicot, N. (2017) · Contrast Media & Molecular Imaging · doi:10.1155/2017/6592139 · Cited by 62
“Limitations of TSPO PET imaging in PSIDs concern the large expression of TSPO in peripheral tissues whereas, in central nervous system, TSPO expression is low in healthy brain [39].”
BackgroundMethodSelf-citationThe emerging role of PET imaging in dementia
Iaccarino, L., Sala, A., Caminiti, S. P., & Perani, D. (2017) · F1000Research · doi:10.12688/f1000research.11603.1 · Cited by 50
“These second-generation ligands come with both 11 C or 18 F isotopes, such as 11 C-PBR28 and 18 F-DPA714, and overall display higher binding affinities 155 .”
BackgroundInfluentialReal, C. C., Doorduin, J., Feltes, P. K., García, D. V., Faria, D. D. P., Britto, L. R. G., & de Vries, E. F. J. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17750351 · Cited by 58
“The correlation between TH staining and [ 18 F]FDOPA uptake was analyzed with a linear regression method.”
BackgroundMethodInfluentialNi, R., Mu, L., & Ametamey, S. M. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0035-5 · Cited by 52
Chauveau, F., Becker, G., & Boutin, H. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05425-w · Cited by 57
Biomarkers of Alzheimer’s disease: Past, present and future clinical use
Georgakas, J. E., Howe, M. D., Thompson, L. I., Riera, N. M., & Riddle, M. C. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100063 · Cited by 58
Gürsel (2018) · doi:10.1016/j.neubiorev.2018.02.005 · Cited by 47
“…of steroid-synthesizing cells including those in the CNS, has been attractive in monitoring microglia activation and brain inflammation, with potential use for diagnosis of neurodegenerative and neuropsychiatric diseases as well as in drug discovery (Dupont et al., 2017; Rupprecht et al., 2010).”
BackgroundZhang, Q., Li, Q., Liu, S., Zheng, H., Ji, L., Yi, N., Bao, W., Zhu, X., Sun, W., Liu, X., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109806 · Cited by 51
Janssen, B., & Mach, R. H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.04.005 · Cited by 45
Imaging temozolomide-induced changes in the myeloid glioma microenvironment
Foray, C., Valtorta, S., Barca, C., Winkeler, A., Roll, W., Müther, M., Wagner, S., Gardner, M. L., Hermann, S., Schäfers, M. A., et al. (2020) · Theranostics · doi:10.7150/thno.47269 · Cited by 52
“Among them, ligands targeting the 18kDa translocator protein (TSPO) have major relevance [17].”
BackgroundZinnhardt, B., Wiesmann, M., Honold, L., Barca, C., Schäfers, M. A., Kiliaan, A. J., & Jacobs, A. H. (2018) · Theranostics · doi:10.7150/thno.24128 · Cited by 50
Simmons, D. A., James, M. L., Belichenko, N. P., Semaan, S., Condon, C., Kuan, J., Shuhendler, A. J., Miao, Z., Chin, F. T., & Longo, F. M. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy202 · Cited by 46
“eral organs and tissues in both rodents and humans (31,32), the in vivo biodistribution of [(18)F]PBR06 was assessed in the heart, kidneys, and interscapular brown adipose tissue of WT and R6/2 mice.”
BackgroundMethodRegulation of Mitochondrial, Cellular, and Organismal Functions by TSPO
Gavish, M., & Veenman, L. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.09.004 · Cited by 51
Zella, M. A. S., Metzdorf, J., Ostendorf, F., Maass, F., Muhlack, S., Gold, R., Haghikia, A., & Tönges, L. (2019) · Cells · doi:10.3390/cells8020105 · Cited by 43
“In contrast, the PET technology for specific labeling of microglial cells has improved and could be integrated with the use of second-generation microglial TSPO tracers [130].”
BackgroundIn search of an anti-inflammatory drug for Alzheimer disease
Gyengesi, E., & Münch, G. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0307-9 · Cited by 43
Microglia as therapeutic targets after neurological injury: strategy for cell therapy
Scott, M. C., Bedi, S. S., Olson, S. D., Sears, C. M., & Cox, C. S. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1934447 · Cited by 46
“brane of mitochondria that was initially discovered as a benzodiazepine-receptor [76].”
BackgroundCorsi, F., Baglini, E., Barresi, E., Salerno, S., Cerri, C., Martini, C., Settimo, F. D., Taliani, S., Gargini, C., & Piano, I. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00582 · Cited by 39
TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma
Pigeon, H., Pérès, E. A., Truillet, C., Jégo, B., Boumezbeur, F., Caillé, F., Zinnhardt, B., Jacobs, A. H., Bihan, D. L., & Winkeler, A. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz029 · Cited by 40
Chemical biomarkers of epileptogenesis and ictogenesis in experimental epilepsy
Luna‐Munguía, H., Zestos, A. G., Gliske, S., Kennedy, R. T., & Stacey, W. C. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.10.005 · Cited by 37
Microglial Dysregulation and Suicidality: A Stress-Diathesis Perspective
Baharikhoob, P., & Kolla, N. J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00781 · Cited by 46
“Examples of third-generation radioligands are [(18)F]-GE180 and [(11)C]-ER176; nonetheless, the safety and efficacy of these compounds in humans have not yet been established (84, 85).”
BackgroundViviano, M., Barresi, E., Siméon, F. G., Costa, B., Taliani, S., Settimo, F. D., Pike, V. W., & Castellano, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220329204054 · Cited by 35
PET Evaluation of Microglial Activation in Non-neurodegenerative Brain Diseases
Ghadery, C., Best, L. A., Pavese, N., Tai, Y., & Strafella, A. P. (2019) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-019-0951-x · Cited by 37
Insight into the Structural Features of TSPO: Implications for Drug Development
Lacapère, J.-J., Duma, L., Finet, S., Kassiou, M., & Papadopoulos, V. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.11.005 · Cited by 36
“Another example to consider would be the a circumstance where TSPO might be in the plasma membrane of astrocytes in CNS [38] or mitochondrial membrane in PNS [5] and thus has different accessibility.”
InfluentialGiridharan, V. V., Collodel, A., Generoso, J. S., Scaini, G., Wassather, R., Selvaraj, S., Hasbun, R., Dal‐Pizzol, F., Petronilho, F. C., & Barichello, T. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1692-0 · Cited by 33
Clinical trials in traumatic brain injury: cellular therapy and outcome measures
Cox, C. S., Juranek, J., & Bedi, S. S. (2019) · Transfusion · doi:10.1111/trf.14834 · Cited by 31
“Neuroinflammation in several neurodegenerative disease processes has been evaluated in vivo with positron emission topography (PET) imaging and radioligands aimed at the 18-kDa translocator protein (TSPO), also known as the peripheral benzodiazepine receptor (PBR).(49) TSPO/PBR is localized to the outer mitochondrial…”
BackgroundPET Imaging of Human Brown Adipose Tissue with the TSPO Tracer [11C]PBR28
Ran, C., Albrecht, D., Bredella, M. A., Yang, J., Yang, J., Liang, S. H., Cypess, A. M., Loggia, M. L., Atassi, N., & Moore, A. V. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1129-z · Cited by 34
Role of PET/CT in diagnosing and monitoring disease activity in rheumatoid arthritis: a review
Singh, S. B., Bhandari, S., Bhandari, S., Bhandari, S., Singh, R., Raynor, W., Hess, S., Werner, T. J., Alavi, A. A., & Revheim, M.-E. R. (2024) · Annals of Nuclear Medicine · doi:10.1007/s12149-023-01896-z · Cited by 37
Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers
Cybulska, K. A., Perk, L. R., Booij, J., Laverman, P., & Rijpkema, M. (2020) · Molecules · doi:10.3390/molecules25030482 · Cited by 29
“Increased TSPO expression has been reported in various neurodegenerative disorders, such as AD, PD and HD [60].”
BackgroundInflammation in Experimental Models of α‐Synucleinopathies
Harms, A. S., Kordower, J. H., Sette, A., Lindestam Arlehamn, C. S., Sulzer, D., & Mach, R. H. (2021) · Movement Disorders · doi:10.1002/mds.28264 · Cited by 29
“1), which is an isotopologue of [(3)H]R-PK11195, the radioligand used in autoradiography studies of tissue obtained from animal models of neuroinflammation.(101) PET imaging studies in both patients with PD and animal models of PD have shown an increase in radiotracer uptake relative to control groups; however, this e…”
BackgroundMethodPicker, L. D., & Haarman, B. C. M. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05308-0 · Cited by 33
Fujinaga, M., Luo, R., Kumata, K., Zhang, Y., Hatori, A., Yamasaki, T., Xie, L., Mori, W., Kurihara, Y., Ogawa, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00374 · Cited by 33
Zukotynski, K., Kuo, P. H., Mikulis, D. J., Rosa‐Neto, P., Strafella, A. P., Subramaniam, R. M., & Black, S. E. (2018) · American Journal of Roentgenology · doi:10.2214/ajr.18.19822 · Cited by 34
Hobson, B. A., Rowland, D. J., Sisó, S., Guignet, M. A., Harmany, Z. T., Bandara, S. B., Saito, N. H., Harvey, D. J., Bruun, D. A., Garbow, J. R., et al. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz096 · Cited by 33
Bruijnen, S., Verweij, N., Gent, Y., Huisman, M., Windhorst, A., Kassiou, M., van de Ven, P. M., Lammertsma, A., Hoekstra, O., Voskuyl, A., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222844 · Cited by 28
Multi‐Omics‐Based Autophagy‐Related Untypical Subtypes in Patients with Cerebral Amyloid Pathology
Park, J., Barahona‐Torres, N., Jang, S., Mok, K. Y., Kim, H. J., Han, S., Cho, K., Zhou, X., Fu, A. K. Y., Ip, N. Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202201212 · Cited by 34
Beaino, W., Janssen, B., Kooijman, E. J. M., Vos, R., Schuit, R. C., O’Brien-Brown, J., Kassiou, M., Hof, B. V. H., Vugts, D. J., de Vries, H. E., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01962-7 · Cited by 31
“Until now, TSPO ligands have been widely used in preclinical and clinical settings to evaluate neuroinflammation in vivo; however, their translation into routine clinical use has been hindered due to polymorphism and complicated quantification of specific binding of tracers [27, 28] in addition to their inability to d…”
Beaurain, M., Salabert, A., Ribeiro, M. J., Arlicot, N., Damier, P., Jeune, F. L., Démonet, J., & Payoux, P. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00268 · Cited by 27
“A new generation of fluorinated tracers has been developed in the past decade (147, 148), with different compound families such as phenoxyarylacetamides derivatives ([18F]FEDAA1106, [18F]-FEPPA, [18F]-PBR06), imidazopyridine derivatives ([18F]-PBR111), and pyrazolopyrimidine derivatives ([18F]-DPA-714) (Figure 3).”
BackgroundSelf-citationKatsumi, Y., Racine, A. M., Torrado-Carvajal, Á., Loggia, M. L., Hooker, J. M., Greve, D. N., Hightower, B. G., Catana, C., Cavallari, M., Arnold, S. E., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102346 · Cited by 28
The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases
Dupont, A.-C., Largeau, B., Guilloteau, D., Ribeiro, M. J., & Arlicot, N. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/7043578 · Cited by 30
“In other neurodegenerative disorders, TSPO PET studies have not achieved convincing results.”
BackgroundInfluentialSelf-citationHosomi, S., Koyama, Y., Watabe, T., Ohnishi, M., Ogura, H., Yamashita, T., & Shimazu, T. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.03.015 · Cited by 26
Perani, D., Iaccarino, L., Lammertsma, A. A., Windhorst, A. D., Edison, P., Boellaard, R., Hansson, O., Nordberg, A. K., Jacobs, A. H., & IMBI Project (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.02.004 · Cited by 27
“(R)-[(11)C]PK11195 was the first and prototypical TSPO tracer [193] and has been largely adopted in neurodegenerative conditions [179,191,194,195].”
BackgroundMethodResultInfluentialDiaz‐Galvan, P., Miyagawa, T., Przybelski, S. A., Lesnick, T. G., Senjem, M. L., Jack, C. R., Forsberg, L. K., Min, H.-K. P., Louis, E. K. S., Savica, R., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcad021 · Cited by 25
“showed that elevated microglial FDG uptake correlated with increased expression of the 18-kDa translocator protein (TSPO) on PET, which has been consistently associated with neuroinflammation.(56) Overall, their results suggest that microglia activation occurring at early stages of neuro-”
BackgroundPulagam, K. R., Colás, L., Padró, D., Plaza‐García, S., Gómez‐Vallejo, V., Higuchi, M., Llop, J., & Martín, A. (2017) · EJNMMI Research · doi:10.1186/s13550-017-0343-7 · Cited by 25
“Moreover, several PET radioligands have been evaluated as markers of microglial neuroinflammation after stroke in both human and animal models [29].”
BackgroundUnconventional non-amino acidic PET radiotracers for molecular imaging in gliomas
Laudicella, R., Quartuccio, N., Argiroffi, G., Alongi, P., Baratto, L., CALIFARETTI, E., Frantellizzi, V., VINCENTIS, G. D., Sole, A. D., Evangelista, L., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05352-w · Cited by 25
Investigation of Inflammation in Lewy Body Dementia: A Systematic Scoping Review
Loveland, P. M., Yu, J. J., Churilov, L. P., Yassi, N., & Watson, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512116 · Cited by 24
“In clinical studies of α-synucleinopathy, TSPO PET studies detect increased microglial activation in disease-relevant brain regions in early PD [14].”
BackgroundBengtsson, S. K. S., Bäckström, T. C., Brinton, R. D., Irwin, R. W., Johansson, M., Sjöstedt, J., & Wang, M. D. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100206 · Cited by 23
“TSPO may be important in Alzheimer's disease as TSPO expression is increased in damaged neural tissue and neuro-inflammation like in AD (Dupont et al., 2017; McNeela et al., 2018).”
BackgroundGlial endozepines and energy balance: Old peptides with new tricks
Lebrun, B., Barbot, M., Tonon, M., Prévot, V., Leprince, J., & Troadec, J. (2020) · Glia · doi:10.1002/glia.23927 · Cited by 22
“These features lead to the use of TSPO ligands for positron emission tomography imaging of neuroinflammation in various neurodegenerative diseases (see Dupont et al., 2017 for review).”
BackgroundPET Neuroimaging in Dementia Conditions
Perani, D., Caminiti, S. P., Carli, G., & Tondo, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_9 · Cited by 21
The aryl hydrocarbon receptor: A diagnostic and therapeutic target in glioma
Lim, T. X., Ahamed, M., & Reutens, D. C. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.021 · Cited by 20
Berroterán-Infante, N., Balber, T., Fürlinger, P., Bergmann, M. M., Lanzenberger, R. R., Hacker, M., Mitterhauser, M., & Wadsak, W. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00367 · Cited by 22
Gopalakrishna, P. K., Nassir, C. M. N. C. M., Anandan, S., Hussan, F., Dandala, K. C. R., Sura, S., Jagadeesan, S., Moklas, M. A. M., Vishnumukkala, T., & Hein, Z. M. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01671-4 · Cited by 25
“The pathogenesis of AD emerges not merely from Aβ and tau aggregation but from the maladaptive sTREM2, and complement components) may provide spatial and temporal maps of neuroinflammation (Dupont et al. 2017 ).”
Giga, H., Ji, B., Kikutani, K., Fukuda, S., Kitajima, T., Katsumata, S., Matsumata, M., Suhara, T., Yamawaki, S., Shime, N., et al. (2020) · Shock · doi:10.1097/shk.0000000000001703 · Cited by 20
“Since bolus administration of LPS is an intoxication model rather than a true septic state, PET imaging study on TSPO in patients with SAE would facilitate the clinical translation of our study.”
BackgroundInfluentialNovel Tracers and Radionuclides in PET Imaging
Mason, C. A., Gimblet, G. R., Lapi, S. E., & Lewis, J. S. (2021) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2021.05.012 · Cited by 21
Sandström, A., Torrado-Carvajal, Á., Morrissey, E. J., Kim, M., Alshelh, Z., Zhu, Y., Li, M., Chang, C. Y., Jarraya, M., Akeju, O., et al. (2023) · Pain · doi:10.1097/j.pain.0000000000003114 · Cited by 18
(R)-[18F]NEBIFQUINIDE: A promising new PET tracer for TSPO imaging
Berroterán-Infante, N., Kalina, T., Fetty, L., Janisch, V., Velasco, R., Vraka, C., Hacker, M., Haug, A. R., Pallitsch, K., Wadsak, W., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.008 · Cited by 19
Tang, D., Fujinaga, M., Hatori, A., Zhang, Y., Yamasaki, T., Xie, L., Mori, W., Kumata, K., Liu, J., Manning, H. C., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.076 · Cited by 17
Foray, C., Barca, C., Winkeler, A., Wagner, S., Hermann, S., Schäfers, M. A., Grauer, O. M., Zinnhardt, B., & Jacobs, A. H. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263318 · Cited by 18
“(TSPO)–targeting PET tracer N,N-diethyl-2-[4-(2-(18)F-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide ((18)FDPA-714), have been used to visualize the myeloid cell compartment in gliomas (12).”
MethodMetzger, J. M., Moore, C. F., Boettcher, C., Brunner, K. G., Fleddermann, R. A., Matsoff, H. N., Resnikoff, H., Bondarenko, V., Kamp, T. J., Hacker, T. A., et al. (2018) · npj Parkinson s Disease · doi:10.1038/s41531-018-0057-1 · Cited by 16
“[(11)C]PBR28 is a second-generation 18-kDa translocator protein (TSPO) ligand.(16,17) TSPO binds cholesterol on the outer mitochondrial membrane; it is present in macrophages and, upon activation, its expression significantly increases.”
BackgroundWolf, B., Brackhan, M., Bascuñana, P., Leiter, I., Langer, B. L. N., Roß, T. L., Bankstahl, J. P., & Bankstahl, M. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00834-5 · Cited by 16
“TSPO is primarily expressed on activated microglia and therefore allows in vivo evaluation of ongoing inflammatory processes [16].”
BackgroundNew PET markers for the diagnosis of dementia
Payoux, P., & Salabert, A. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000489 · Cited by 15
Characterization of the High-Affinity Drug Ligand Binding Site of Mouse Recombinant TSPO
Iatmanen-Harbi, S., Sénicourt, L., Papadopoulos, V., Lequin, O., & Lacapère, J.-J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061444 · Cited by 16
“Many TSPO ligands belonging to different chemical classes have been identified over the last decades [4], but overly complex binding profiles likely due to the number of genetic variants [7] as well as the lack of atomic structures have not permitted the optimization of drug design [8].”
BackgroundFrom Monoamines to Systems Psychiatry: Rewiring Depression Science and Care (1960s–2025)
Tanaka, M. (2025) · Biomedicines · doi:10.3390/biomedicines14010035 · Cited by 20
“Transla-tionally, positron emission tomography ligands, cerebrospinal cytokine panels, and electroencephalographic complexity measures provide convergent markers of central immune engagement [85–88].”
Verveen, A., Verfaillie, S. C. J., Visser, D., Csorba, I., Coomans, E. M., Koch, D. W., Appelman, B., Barkhof, F., Boellaard, R., de Bree, G. J., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072611 · Cited by 14
Infection and Inflammation Imaging
Kircher, M., & Lapa, C. (2020) · PET Clinics · doi:10.1016/j.cpet.2019.11.004 · Cited by 15
In vivo PET Imaging of Gliogenesis After Cerebral Ischemia in Rats
Ardaya, M., Joya, A., Padró, D., Plaza‐García, S., Gómez‐Vallejo, V., Sánchez, M., Garbizu, M., Cossío, U., Matute, C., Cavaliere, F., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00793 · Cited by 13
Cigarette smoke, saliva, the translocator protein 18 kDa (TSPO), and oral cancer
Nagler, R. M., Weizman, A., & Gavish, A. (2019) · Oral Diseases · doi:10.1111/odi.13178 · Cited by 14
Wang, L., Yao, S., Tang, R., Zhu, H., Zhang, L., Gong, J., Chen, Q., Collier, T. L., Xu, H., & Liang, S. H. (2020) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3824 · Cited by 13
Metadata
- Authors
- Dupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N.
- Affiliations
- Inserm (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- CHRU Tours, 2 Boulevard Tonnellé, 37044 Tours, France
- Corresponding author
- Dupont, Anne-Claire
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-04-07
- Volume
- 18
- Issue
- 4
- Pages
- 785
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5412369
- OpenAlex
- W2605220880
- Cited by
- 182
- References
- 249
- Citations by year
- 2026: 16 · 2025: 14 · 2024: 10 · 2023: 12 · 2022: 14 · 2021: 13 · 2020: 34 · 2019: 31 · 2018: 25 · 2017: 13
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Funders
- Agence Nationale de la Recherche (ANR-11-LABX-0018)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- translocator protein (TSPO), TSPO PET imaging, microglial activation, neuroinflammation, neurodegenerative diseases, Parkinson's disease, Huntington's disease, dementia, amyotrophic lateral sclerosis, multiple sclerosis, mental illness, molecular biomarkers, radiopharmaceuticals, multiplexed imaging, cytokines, metabolomics
- MeSH terms
- Humans, Biomarkers, Up-Regulation, Microglia, Receptors, GABA, Radiopharmaceuticals, Neurodegenerative Diseases, Early Diagnosis, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.